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Abstract. The receptor for advanced glycation end products 
(RAGE) is a multi-ligand cell surface receptor and a member of 
the immunoglobulin superfamily. RAGE is involved in a wide 
range of inflammatory, degenerative and hyper‑proliferative 
disorders which span over different organs by engaging diverse 
ligands, including advanced glycation end products, S100 
family proteins, high-mobility group protein B1 (HMGB1) 
and amyloid β. We previously demonstrated that the cyto-
plasmic domain of RAGE is phosphorylated upon the binding 
of ligands, enabling the recruitment of two distinct pairs of 
adaptor proteins, Toll-interleukin 1 receptor domain-containing 
adaptor protein (TIRAP) and myeloid differentiation protein 88 
(MyD88). This engagement allows the activation of downstream 
effector molecules, and thereby mediates a wide variety of 
cellular processes, such as inflammatory responses, apoptotic 
cell death, migration and cell growth. Therefore, inhibition of 
the binding of TIRAP to RAGE may abrogate intracellular 
signaling from ligand-activated RAGE. In the present study, we 
developed inhibitor peptides for RAGE signaling (RAGE-I) by 
mimicking the phosphorylatable cytosolic domain of RAGE. 
RAGE‑I was efficiently delivered into the cells by polyethyl-
enimine (PEI) cationization. We demonstrated that RAGE-I 
specifically bound to TIRAP and abrogated the activation of 
Cdc42 induced by ligand-activated RAGE. Furthermore, we 
were able to reduce neuronal cell death induced by an excess 
amount of S100B and to inhibit the migration and invasion of 
glioma cells in vitro. Our results indicate that RAGE-I provides 
a powerful tool for therapeutics to block RAGE-mediated 
multiple signaling.
Introduction
The receptor for advanced glycation end products (RAGE) 
belongs to the immunoglobulin superfamily of cell surface 
receptors. It comprises of three domains, an extracellular 
domain (with one V-type and two C-type domains), a trans-
membrane-spanning domain and a cytoplasmic domain (1). 
RAGE is activated by binding to a diverse repertoire of 
ligands (2). These ligands include advanced glycation end 
products (AGEs) (3), S100 family proteins (4-6), high-mobility 
group box 1 (HMGB1) (5,7) and amyloid β (Aβ) peptides (8). 
Activated RAGE triggers multiple intracellular pathways, 
such as the production of reactive oxygen species, the 
activation of p21ras, Erk1/2 (p44/p42) mitogen-activated 
protein kinases, p38 and stress-activated protein kinase 
(SAPK)/c-Jun N-terminal kinase (JNK) mitogen-activated 
protein kinases, rhoGTPases, phosphatidylinositol-3 kinase 
and Janus kinase (JAK)/signal transducers and activators of 
transcription (STAT), eventually leading to the activation 
of nuclear factor-κB (NF-κB), activator protein-1 (AP-1) and 
STAT-3 (9-12).
RAGE is physiologically expressed in multiple tissues 
during embryonic development, but is mostly downregulated 
as cells reach homeostasis in adult life. Therefore, with the 
exception of the skin and lungs, RAGE expression is kept at 
low levels in the adult body (13,14). The binding of ligands and 
the increased expression of RAGE potentially lead to inflam-
mation-associated pathological conditions, such as those found 
in neurodegenerative diseases (8,15,16), cardiovascular and 
renal diseases (17,18), pulmonary diseases (19), diabetes and 
metabolic disorders (20,21), as well as cancer (22). Under such 
conditions, NF-κB activated by RAGE signaling enhances the 
expression of RAGE, thus composing a self-sustaining positive 
feedback loop. Therefore, RAGE is one of the most promising 
targets for the development of therapeutic methods.
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Antagonistic RAGE peptides (23,24), RAGE-blocking 
antibodies (25) and ligand-binding drugs (26) have been 
examined in an effort to inhibit or abrogate RAGE signaling. 
These studies focused on the extracellular domain of RAGE 
and its various ligands. On the other hand, we have previ-
ously found that the short cytoplasmic domain of RAGE is 
phosphorylated at serine 391 (Ser391) by protein kinase C, 
zeta (PKCζ) upon ligand binding. The phosphorylated domain 
then recruits Toll-interleukin 1 receptor domain-containing 
adaptor protein (TIRAP), an adaptor protein for TLR2/4 (27), 
and transduces a signal to downstream molecules. Since the 
RAGE-TIRAP interaction is commonly induced by diverse 
ligands, such as AGEs, S100 proteins and HMGB1, an inhibi-
tory tool for the interaction between RAGE and TIRAP may 
efficiently abrogate RAGE‑mediated signaling regardless of 
ligand species. In the present study, we developed inhibitor 
decoy peptides for RAGE signaling (RAGE-I) by mimicking 
the phosphorylated cytosolic domain of RAGE. RAGE-I was 
cationized by polyethylenimine (PEI) for its efficient delivery 
into target cells, as previously described (28). We showed that 
RAGE-I, delivered intracellularly, bound to TIRAP and miti-
gated RAGE-mediated signaling. Neuronal cell death induced 
by an excess amount of S100B and the migration and invasion 
of glioma cells were suppressed by the application of RAGE-I 
in vitro. Our results indicate that RAGE-I provides a powerful 
therapeutic tool for the blocking of RAGE-mediated multiple 
signaling.
Materials and methods
Preparation of PEI‑avidin and biotinylated RAGE‑I. To 
efficiently deliver inhibitor peptides into cells, PEI‑avidin was 
used as the vehicle as previously described (28). Avidin was 
coupled with PEI600 (both from Wako Chemicals, Osaka, 
Japan) by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC; Pierce, Rockford, IL, USA) [avidin 
(2.5 mg/ml) in PEI600-solution (100 mg/ml, pH 5.0) and 
0.1 mg/ml EDC] for 16 h at room temperature. After the 
reaction, the solution was exhaustively dialyzed against PBS. 
Inhibitor peptides were designed to function as a decoy by 
binding to TIRAP, mimicking the cytoplasmic sequence 
of RAGE (387-395 amino acids). Ser391 was replaced with 
alanine [RAGE(A)-I, non-phosphorylatable] or with glutamic 
acid [RAGE(E)-I, phosphorylation mimic] (Fig. 1). The 
peptides were biotinylated under conventional conditions. In 
SS‑RAGE(E)‑I, a disulfide bond was introduced between the 
peptide and biotin to facilitate the release of RAGE(E)-I from 
the PEI-avidin vehicle under intracellular reducing conditions 
as previously described (29,30).
Cells, chemicals and antibodies. SH-SY5Y human neuro-
blastoma, U-87MG human glioblastoma, B16-BL6 mouse 
melanoma and HEK293 human embryonic kidney cells were 
cultured in D/F medium supplemented with 10% fetal bovine 
serum (both from Life Technologies, Carlsbad, CA, USA).
The antibodies used were as follows: goat polyclonal anti-
body against glutathione S-transferase (GST; GE Healthcare, 
Waukesha, WI, USA); mouse monoclonal antibody against 
Myc and HRP-labeled anti-mouse secondary antibody (Cell 
Signaling Technologies, Beverly, MA, USA). The Rac/Cdc42 
Activation Assay kit was purchased from Millipore (Billerica, 
MA, USA). Endo-Porter was purchased from Gene Tools, 
LLC (Philomath, OR, USA).
Purification of recombinant proteins. GST, GST-TIRAP, 
GST-myeloid differentiation protein 88 (MyD88), GST-thyroid 
receptor activator molecule (TRAM) and GST-S100B proteins 
were purified from the bacterial lysates of BL21 competent 
cells transformed with pGEX6P1 vectors containing each 
cDNA using glutathione sepharose beads (GE Healthcare) 
according to the standard procedures outlined by the manu-
facturer. For the purification of S100B, GST-S100B was 
incubated with PreScission protease (1 U/100 µg of GST-S100B; 
GE Healthcare) for the cleavage of GST. GST was removed 
using glutathione sepharose beads. The purity of the proteins 
was determined by SDS-PAGE.
Pull‑down assay and western blot analysis. Biotinylated 
peptides were incubated with GST-proteins or cell lysates for 
2 h. The pull-down of biotinylated peptide-protein complexes 
was carried out using streptavidin-coupled Dynabeads (Life 
Technologies).
Western blot analysis was performed under conventional 
conditions after lysing the cells with M-PER Mammalian 
Protein Extraction Reagent (Thermo Scientific, Lafayette, 
CO, USA) with PhosphoSTOP (Roche Applied Science, 
Indianapolis, IN, USA).
Apoptosis assay, migration assay and invasion assay. For 
apoptosis assay, the SH-SY5Y cells were cultured with 
D/F-0.5% FBS for 24 h prior to incubation with GST or 
S100B at 0‑10 µM for 24 h. Apoptotic cells were identified 
after staining with Hoechst 33342 (Life Technologies) for 
30 min. For migration assay, 10,000 U-87MG cells incubated 
with inhibitor peptides in advance were inoculated into the 
top wells of Boyden chambers (pore size, 8 µm; BD Falcon, 
Franklin Lakes, NJ, USA). The filters were stained after 
incubation for 8 h and the migrated cells were counted. For 
invasion assay, 25,000 U-87MG cells incubated with inhibitor 
peptides in advance were inoculated into the top wells of 
Boyden chambers pre-coated with growth factor-reduced 
Matrigel (Life Technologies). The filters were stained after 
incubation for 8 h and invaded cells were counted.
Cell counting and cell growth assay. Cells were counted using 
a haemocytometer after staining with 0.5% trypan blue. Each 
experiment was repeated at least three times. For cell growth 
assay, the CellTiter-Glo Luminescent Cell Viability Assay 
system (Promega Biosciences, San Luis Obispo, CA, USA) 
was used. The experiment was carried out according to the 
manufacturer's instructions.
Rac/Cdc42 activation assay. The experiment was performed 
using the Rac1/Cdc42 Activation kit (Millipore) according to 
the manufacturer's instructions. U-87MG cells were treated 
with PEI-avidin/biotin-inhibitor peptides for 24 h. The 
activation of Cdc42 (GTP bound form) was determined by 
pull-down assay using GST-PAK-1 (containing 67-150 amino 
acids) and glutathione sepharose beads followed by western 
blot analysis.
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Statistical analysis. Prior to statistical analysis, each 
experiment was repeated at least three times. The results are 
expressed as the means ± SD. For comparison, analysis of 
variance (ANOVA) was used. If ANOVA showed significant 
differences, the Bonferroni procedure was used as a post hoc 
test. P-values <0.05 were considered to indicate statistically 
significant differences.
Results
Preparation and intracellular delivery of RAGE‑I. In our 
previous study, we showed that the phosphorylation of Ser391 
of the intracellular domain of RAGE by PKCζ was critical 
for recruiting the downstream signal transducer, TIRAP (27). 
In this study, we therefore designed decoy peptides covering 
the serine residue, i.e., 387-395 of RAGE. As shown in Fig. 1, 
we prepared three peptides, RAGE(A)-I, RAGE(E)-I and 
SS-RAGE(E)-I (see Materials and methods). Two inhibitor 
peptides for TIRAP (TIRAP-I) and MyD88 (MyD88-I), which 
were already reported to function as a decoy for TLR2/4 by 
binding to the TIR domain of TIRAP and MyD88 (31,32), were 
included for comparison. The peptides were biotinylated for 
intracellular delivery using avidin conjugated with PEI-avidin. 
PEI cationization is a powerful tool used to deliver a protein 
or peptide into cells (28). To confirm the efficient transduc-
tion of biotinylated molecules by PEI-avidin, we examined 
the intracellular delivery of biotin-GFP using B16-BL6 
mouse melanoma, SH-SY5Y human neuroblastoma and 
U-87MG human glioblastoma cells. As shown in Fig. 2, the 
PEI-avidin/biotin-GFP complex, but not the biotin-GFP alone 
Figure 1. Constructs of receptor for advanced glycation end products (RAGE) inhibitor peptides (RAGE-I). Cytoplasmic region of RAGE (387-395 amino 
acids) interacting with the adaptor protein Toll-interleukin 1 receptor domain-containing adaptor protein (TIRAP) was used as a template for RAGE inhibitor 
peptides. Ligand-induced phosphorylation site of Ser391 was replaced either with non-phosphorylatable alanine [RAGE(A)-I] or with phosphorylation-mimic 
glutamic acid [RAGE(E)-I]. The inhibitor peptides were biotinylated for intracellular delivery using a polyethylenimine (PEI)-avidin vehicle. SS-RAGE(E)-I 
contains a disulfide bond between biotin and the peptide. SS‑RAGE(E)‑I can be released from the vesicle under intracellular reducing conditions. Inhibitor 
peptides for TIRAP (TIRAP-I) and myeloid differentiation protein 88 (MyD88)-I are known to function as decoys by binding to the TIR domain.
Figure 2. Intracellular delivery of biotinylated GFP. B16-BL6, SH-SY5Y and U-87MG cells were incubated with 1 µM biotin-GFP and/or PEI-avidin for 
6 h. Endo-Porter was added to the medium immediately after the addition of the proteins. The cells were washed thoroughly before being observed under a 
fluorescence microscope. Bar scale, 200 µm.
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was delivered efficiently into the cells. Cationized molecules 
are known to incorporate into cells through the macropinocy-
tosis pathway (33) and Endo-Porter is known to enhance the 
release of incorporated molecules from the endosome to the 
cytoplasm (30). The fluorescence from intracellular GFP was 
intensified and showed a more diffused pattern in the cytoplasm 
by application of the cells with Endo-Porter (Fig. 2). Therefore, 
we used the combination of PEI-avidin and Endo-Porter for 
the intracellular delivery in the following experiments.
Direct binding of RAGE(E)‑I to TIRAP. We prepared 
GST-fused TIRAP and other adaptor proteins of Toll-like 
receptors, MyD88 and TRAM, and incubated them with 
RAGE(E)-I in vitro. We detected only TIRAP in the 
pulled-down fraction of RAGE(E)-I, indicating the direct 
binding of the inhibitor peptide to TIRAP, but not to MyD88 
and TRAM (Fig. 3A). We then examined the significance of the 
phosphorylation site at Ser391 of RAGE-I for interaction with 
TIRAP. Biotinylated RAGE-I was incubated with cell lysates 
expressing Myc-TIRAP, pulled-down with streptavidin beads, 
and analyzed by western blot analysis. As shown in Fig. 3B, 
phosphorylation-mimic RAGE(E)-I strongly interacted with 
TIRAP, whereas non-phosphorylatable RAGE(A)-I did not 
show any appreciable binding with TIRAP. These results indi-
cate that RAGE(E)-I is a promising tool for interfering with 
RAGE signaling through a decoy function for TIRAP.
RAGE‑I protects cell death induced by S100B. Huttunen et al (5) 
reported that relatively high concentrations (5 µM) of S100B 
induced apoptosis in neuronal cells. In this study, after 
confirming the cytotoxic effects of 10 µM S100B on SH‑SY5Y 
cells (Fig. 4B), we examined whether the prophylactic appli-
cation of RAGE-I reduces S100B-induced cytotoxicity in 
SH‑SY5Y cells. We highly purified recombinant human S100B 
protein (Fig. 4A, lane 7) and treated the cells with the protein. 
By monitoring nuclear shrinkage with Hoechst staining, an 
assessment of apoptotic cell death, we found that the excess 
amount of S100B (10 µM) induced an increase in apoptotic 
cell death (Fig. 4B). By contrast, the prophylactic addition 
of RAGE(E)-I, SS-RAGE(E)-I, TIRAP-I and MyD88-I, 
but not RAGE(A)-I attenuated the apoptotic ratio (Fig. 4C). 
SS-RAGE(E)-I showed almost the same effect in comparison 
with TIRAP-I and MyD88-I. These results indicate that the 
signaling from RAGE-TIRAP interaction plays a critical role 
in the induction of S100B-mediated cell death and that this may 
be prevented by pre-treatment of the cells with RAGE inhibitor 
peptides.
RAGE‑I inhibits cell migration and invasion, but not cell 
growth. It is known that the activation of RAGE results 
in enhanced migration and invasion of various types of 
cells (34,35). Therefore, we also investigated whether RAGE-I 
inhibits the migration and invasion of U-87MG glioblastoma 
cells in vitro. When the cells were treated with RAGE-I, 
the migration and invasion of the cells were significantly 
suppressed (Fig. 5A and B). In addition, these results correlated 
with the inactivation of Cdc42 (Fig. 5C), which is closely asso-
ciated with RAGE-mediated cell migration (36,37). A higher 
suppression was observed in the SS-RAGE(E)-I-treated group 
compared with the RAGE(E)-I-treated group (Fig. 5A-C). 
This possibly occurred as RAGE(E)-I was released from 
biotin‑PEI‑avidin and more efficiently captured endogenous 
TIRAP. Under similar conditions, the growth of U-87MG cells 
was not significantly affected as assayed by determining the 
intracellular adenosine triphosphate (ATP) content (Fig. 5D), 
or by counting the number of cells (Table I). These results 
indicate that RAGE-I effectively abrogates the downstream 
signaling of ligand-activated RAGE in glioblastoma cells in 
terms of migration and invasion.
Discussion
RAGE plays pivotal roles in a variety of physiological contexts, 
including early development. On the other hand, the aberrant 
hyperfunctional state of RAGE due to the overexpression 
of RAGE and/or the overstimulation of RAGE by ligands is 
involved in a variety of pathological conditions, including 
diabetic syndrome, cancer and neurodegenerative diseases. 
Thus, interfering with RAGE function is considered a potent 
therapeutic measure. Abe et al (25) reported that RAGE was 
Figure 3. Binding of inhibitor peptides for receptor for advanced glycation end products (RAGE) signaling (RAGE-I) to Toll-interleukin 1 receptor 
domain‑containing adaptor protein (TIRAP). (A) Biotinylated RAGE(E)‑I was incubated with purified GST‑fused proteins in vitro and was pulled-down using 
streptavidin-beads. Binding of RAGE(E)-I to TIRAP was detected by western blot analysis. (B) The lysates of HEK293 cells expressing Myc-TIRAP were 
incubated with biotinylated RAGE(A)-I or biotinylated RAGE(E)-I for 2 h. The binding of RAGE inhibitor peptides to TIRAP was determined by pull-down 
with streptavidin-beads followed by western blot analysis (WB).
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overexpressed in human melanoma cells and that AGE stimu-
lated the growth and migration of the cells. They showed that 
the application of an antibody against the extracellular domain 
of RAGE suppressed the growth of melanoma cells in vitro 
and in vivo. Huttunen et al (23) demonstrated that a C-terminal 
motif of amphoterin (150-183 amino acids) bound to RAGE 
and inhibited the migration and invasion of human fibrosar-
coma cells. Arumugam et al (24) prepared S100P-derived 
small peptides. The peptide inhibited the interaction of 
S100P, S100A4 and HMGB-1 with RAGE and abrogated 
the growth of pancreatic tumors and glioma. In Alzheimer's 
disease (AD), the Aβ peptide accumulates in plaque in the 
brain. RAGE mediates Aβ-induced perturbations in cerebral 
vessels, neurons and microglia in AD. Deane et al (38) identi-
fied a high‑affinity RAGE‑specific inhibitor (FPS‑ZM1) that 
blocked Aβ binding to the V domain of RAGE and inhibited 
Aβ40- and Aβ42-induced cellular stress in RAGE-expressing 
cells in vitro and in the mouse brain in vivo.
These studies focused on the extracellular domain of 
RAGE and its various ligands. On the other hand, we focused 
on the intracellular domain of RAGE based on our previous 
findings of RAGE‑TIRAP interaction (27). Inhibitor peptides 
were designed by mimicking the phosphorylated cytosolic 
domain of RAGE. Since the RAGE-TIRAP interaction is a 
common converged event for diverse ligands such as AGE, 
S100 proteins and HMGB1, we hypothesized that an inhibi-
Figure 4. Mitigation of S100B-related cell death by inhibitor peptides for receptor for advanced glycation end products (RAGE) signaling (RAGE-I). 
(A) Expression and purification of S100B from E. coli. The purity of S100B was confirmed by SDS‑PAGE. Lane 1, E. coli lysates without isopropyl β-D-1-
thiogalactopyranoside (IPTG) induction; lane 2, induction of GST-S100B with IPTG; lane 3, precipitates after lysis; lane 4, supernatants after lysis; lane 5, 
GST‑S100B after purification with Sephadex 4B‑column; lane 6, cleavage of GST from S100B by PreScission protease; lane 7, purified S100B. (B) Induction 
of apoptosis by S100B. SH‑SY5Y cells were incubated with control GST or S100B for 24 h. Apoptotic cells were identified after staining with Hoechst 33342. 
*P<0.05, significantly different from the control group. (C) Polyethylenimine (PEI)‑avidin/biotin‑inhibitor peptides (1 µM) were added to the SH‑SY5Y cells for 
12 h prior to treatment with GST or S100B (10 µM, 24 h). Apoptotic cells were identified after staining with Hoechst 33342. Statistically significant differences 
were determined by comparing with the cells without S100B. *P<0.05, significantly different from the control group with S100B; ns, not significant.
Table I. Treatment with inhibitor peptides did not affect the 
growth of U-87MG cells.
Groups No. of cells (x105)
Control 10.9±0.8
RAGE(A)-I 10.7±0.5
RAGE(E)-I 10.5±0.5
SS-RAGE(E)-I 10.8±0.7
TIRAP-I 10.9±0.8
MyD88-I 10.7±0.7
RAGE, receptor for advanced glycation end products; RAGE-I, 
inhibitor peptides for RAGE signaling; TIRAP, Toll-interleukin 1 
receptor domain-containing adaptor protein; MyD88, myeloid dif-
ferentiation protein 88.
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tory tool for the interaction between RAGE and TIRAP may 
efficiently abrogate RAGE‑mediated signaling regardless of 
ligand species.
RAGE has been demonstrated to play a significant role in the 
development of several degenerative and inflammation‑related 
diseases (8,15,17-22). In the present study, we monitored cellular 
behavior related with two pathological conditions, neuronal cell 
death and the migration and invasion of cancer cells. Griffin 
et al (39) and Mrak and Griffinbc (40) demonstrated that S100B 
contributes to the progression of AD. In the present study, we 
demonstrated that the addition of S100B induced the apoptosis 
of SH-SY5Y cells and that the pre-treatment of the cells with 
RAGE inhibitor peptides resulted in the mitigation of apoptosis. 
The decrease in apoptosis suggests that RAGE-TIRAP interac-
tion is one of the targets for the prevention of neurodegeneration. 
In cancer cells, cell migration and invasion are considered, at 
least in part, to occur due to the hyperfunction of RAGE (25). 
Since the high expression of RAGE and its ligands have previ-
ously been found in many cancer cases (22), in this study, we 
tried to inhibit cell migration and invasion by RAGE-I using 
U-87MG human glioblastoma cells. As expected, the treatment 
of U-87MG cells with RAGE-I resulted in the suppression of 
migration and invasion. The reduced migration and invasion 
appeared not be due to cytotoxicity as the cell growth was not 
affected (Table I) (Fig. 5D).
Protein transduction (PTD) sequences such as TAT, polyar-
ginine and antennapedia are widely used for the intracellular 
delivery of proteins and peptides (33). Although the inhibitor 
peptides for TIRAP and MyD88 conjugated with the PTD 
sequence (Imgenex) are available, the recommended concen-
tration for application is ~100 µM. The necessity for high 
concentrations of the agents hampers the practical application 
of these peptides for future clinical, as well as experimental 
use. We demonstrated that PEI-avidin delivers biotinylated 
peptides at 1 µM into cells and that the delivered peptides 
can function sufficiently. The addition of disulfide bonds to 
facilitate the release of the peptide from PEI-avidin under 
intracellular reducing conditions enhanced the efficiency of 
the inhibitor peptides. These data indicate that our approach 
provides a promising tool, not only for the analysis of the 
etiology of RAGE-related disorders, but also for the develop-
ment of therapeutic measures against such diseases.
Figure 5. Inhibitor peptides for receptor for advanced glycation end products (RAGE) signaling (RAGE-I) suppress migration and invasion of glioma cells but 
not proliferation. U-87MG cells were incubated with 1 µM polyethylenimine (PEI)-avidin/biotin-inhibitor peptides for 24 h for the (A) migration and (B) inva-
sion assays and (C) determination of active Cdc42 (GTP bound form). (D) U-87MG cells were incubated with 1 µM PEI-avidin/biotin-inhibitor peptides for 
24 h. The level of ATP was determined using CellTiter-Glo assay. *P<0.05, significantly different from the control group; ns, not significant.
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